

Keyword Index

- 5-azacytidine, 101109
- FLT3* inhibitor, 101109
- Acute GVHD, 101111
Acute lymphoblastic leukemia, 101095
Acute myeloid leukemia, 101094
Adoptive immunotherapy, 101109
ALL, 101095
ALL subtype, 101095
Allogeneic, 101109
Allogeneic HCT, 101111
Allogeneic transplantation, 101112
Amino acid metabolism, 101100
AML, 101094
AZA, 101109
Azacitidine, 101100
- B-ALL, 101095
B-progenitor ALL, 101095
Beat AML, 101101
Biomarkers, 101111
BMME, 101113
Bone abnormalities, 101113
Bone marrow microenvironment, 101113
- CAR, 101097
CAR-T, 101097
CART, 101104
CBF, 101102
CD123, 101104
CD33, 101104
Chimeric antigen receptor, 101097
Chimeric antigen receptor T cell, 101104
Clonal hematopoiesis of indeterminate potential, 101099
Complete response, 101106
Core binding factor, 101102
CPX-351, 101094
CR, 101106
Crenolanib, 101103
CRLF2, 101096
Cytokine receptor-like factor 2, 101096
- Dasatinib, 101096
DUX4, 101095
- Early diagnosis, 101099
Elderly, 101105
Enasidenib, 101094
ETV6-RUNX1, 101095
- FLT3*, 101094
fms-related tyrosine kinase 3, 101106
Fratricide resistant, 101097
- Gemtuzumab ozogamicin, 101094
Genome profiling, 101095
GI tract, 101111
Gilteritinib, 101094
Glasdegib, 101094
Graft-versus-host disease, 101109
Graft-versus-leukemia, 101109
GVHD, 101109
GVL, 101109
- Haploidentical, 101110
HCT, 101109
Hematopoietic cell transplantation, 101109
Hematopoietic stem and progenitor cell, 101113
Hematopoietic stem cell transplantation, 101108
Hematopoietic stem cells, 101113
HiDAC, 101102
High-dose cytarabine, 101102
HSC, 101113
HSCT, 101108
HSPC, 101113
Hypodiploid, 101095
Hypomethylating agents, 101109
- IDAC, 101102
IDH1/2, 101106
IDH2, 101102
IGH, 101095
IKZF1, 101095
Immunophenotype, 101100
Induction, 101094
Intermediate-dose cytarabine, 101102
Isocitrate dehydrogenase-1/2, 101106
Ivosidenib, 101094
- LDAC, 101102
Leukemia stem cell, 101100
Low-dose cytarabine, 101102
LSC, 101100
- Maintenance, 101109
MDS, 101098
Measurable residual disease, 101102
MEF2D, 101095
Microenvironment, 101101
Midostaurin, 101094
Minimal residual disease, 101108
Model, 101098
MRD, 101102
Mutations, 101098
Myelodysplastic syndromes, 101098
- Non-relapse mortality, 101111
NRM, 101111
NUTM1, 101095

Off-the-shelf, 101097
Older patient, 101110
OS, 101106
Osteoblastic lineage, 101113
Overall survival, 101106
Oxidative phosphorylation, 101100

Pathogenesis, 101101
PAX5, 101095
Ph-like, 101095
Ph-like ALL, 101096
Philadelphia chromosome-like, 101096
Post-remission, 101102
Post-transplant cyclophosphamide, 101112

Quizartinib, 101103

Reduced intensity conditioning, 101110
Ruxolitinib, 101096

Sorafenib, 101103

T-ALL, 101097
T-cell acute lymphoblastic leukemia, 101097
Taxonomy, 101095
TKI, 101096
Transformation, 101098
Transplant related mortality, 101110
Treatment selection, 101099
Tumor-associated macrophage, 101101
Tyrosine kinase inhibitor, 101096
Tyrosine kinase inhibitors, 101103

UCART7, 101097
Umbilical cord blood, 101110
Unlearning, 101112

Venetoclax, 101094

ZNF384, 101095